Acute Resistance Exercise and Hydrolyzed Collagen Supplementation

January 31, 2024 updated by: Rob Erskine

The Dose-response of Vitamin C-enriched Collagen on Markers of Collagen Synthesis in Middle-Aged Men and Women Following Resistance Exercise

This study aimed to investigate the effect of different doses of hydrolyzed collagen (HC) with resistance exercise (RE) on whole body collagen synthesis in middle-aged males and females.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study aimed to investigate the effect of different doses of hydrolyzed collagen (HC) with resistance exercise (RE) on whole body collagen synthesis in healthy middle-aged males and females.

Healthy middle-aged males and females ingested 0 grams, 15 grams or 30 grams HC with 50 milligrams vitamin C 1h prior to performing four sets' leg press RE at 10-repetition maximum load, after which they rested for six hours. Blood samples were collected throughout each trial to analyse procollagen type Ⅰ N-terminal propeptide (PⅠNP, a biomarker of collagen synthesis) and β-isomerized C-terminal telopeptide of type I collagen (β-CTX, a biomarker of collagen breakdown) concentration, and the concentration of 18 amino acids that constitute collagen.

This is the first study to investigate the combined effect of different doses HC with high-intensity RE on whole body collagen synthesis in middle-aged men and women. If 30 grams HC intake with RE does augment collagen synthesis more than RE alone, this suggests that long-term HC intake with chronic RE would be beneficial for tendon health, because collagen is the most abundant protein in tendon.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • At least 12 months experienced in resistance exercise (including weekly lower body exercise)
  • Free from musculoskeletal injury

Exclusion Criteria:

  • Having a history of patellar tendon pathology
  • Vegan
  • Consumed nutritional supplements or medication purported to have beneficial effects on muscle-tendon properties (e.g. antioxidants, protein, etc.)
  • Had a sustained a lower limb injury in the previous six months
  • Smoker/vaper
  • Having reached menopause (only for middle-aged female participants)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention for middle-aged men: Consumption of hydrolyzed collagen (HC) with resistance exercise
Middle-aged male participants consumed one of three different HC doses (0 grams, 15 grams, or 30 grams) with 4 sets of 10 repetitions of leg press exercise at 10-repetition maximum load in a random order and a seven-day wash-out period interspersed between each trial.
Dietary supplement: Consumption of three different doses of hydrolyzed collagen (HC) with resistance exercise

Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.

All interventions were performed at the same time of day (08:00 - 15:00).

Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.

The details of dietary supplements used are as follows:

Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)

Other Names:
  • Resistance exercise and collagen dose-response for middle-aged male participants
Experimental: Intervention for middle-aged women: Consumption of hydrolyzed collagen (HC) with resistance exercise
The intervention procedure is exactly same as Arm 1 except for the number of visits and doses of HC. Middle-aged female participants were asked to visit the laboratory on the day of highest oestrogen (i.e. ovulation) and provided with 0 g or 30 g HC. Dates for the trials were determined based on self-report of onset of menses and previous menstrual cycle length.
Dietary supplement: Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise

Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.

All interventions were performed at the same time of day (08:00 - 15:00).

Different doses of HC (0 grams, and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.

The details of dietary supplements used are as follows:

Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)

Other Names:
  • Resistance exercise and collagen dose-response for middle-aged female participants

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in a marker of collagen synthesis
Time Frame: At rest immediately prior to HC ingestion, 0.5-hour post RE, 1-hour post RE, 2-hour post RE, 4-hour post RE and 6-hour post RE
Serum procollagen type Ⅰ N-terminal propeptide (PⅠNP) concentrations were measured following 0 grams, 15 grams or 30 grams hydrolyzed collagen (HC) intake with resistance exercise (RE) during all interventions.
At rest immediately prior to HC ingestion, 0.5-hour post RE, 1-hour post RE, 2-hour post RE, 4-hour post RE and 6-hour post RE
Change in a marker of collagen breakdown
Time Frame: At rest, immediately prior to HC ingestion, 0.5-hour post RE, 2-hour post RE and 6-hour post RE
Plasma β-isomerized C-terminal telopeptide of type I collagen (β-CTX) concentrations were measured following 0 grams, 15 grams or 30 grams hydrolyzed collagen (HC) intake with resistance exercise (RE) during all interventions.
At rest, immediately prior to HC ingestion, 0.5-hour post RE, 2-hour post RE and 6-hour post RE

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Estrogen concentrations in women in each trial
Time Frame: At rest immediately prior to HC ingestion
Concentrations of estrogen (17β-estradiol) was measured in each intervention.
At rest immediately prior to HC ingestion
Changes in amino acids concentrations in blood
Time Frame: At rest immediately prior to HC ingestion, 0.5-hour post HC ingestion, 1-hour post HC ingestion, 0.5-hour post RE, 1-hour post RE, 2-hour post RE, 4-hour post RE and 6-hour post RE
Concentration of serum amino acids that constitute collagen was measured following 0 grams, 15 grams or 30 grams hydrolyzed collagen (HC) intake with resistance exercise (RE) during all interventions.
At rest immediately prior to HC ingestion, 0.5-hour post HC ingestion, 1-hour post HC ingestion, 0.5-hour post RE, 1-hour post RE, 2-hour post RE, 4-hour post RE and 6-hour post RE

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Rob Erskine

Collaborators

University of East Anglia

Investigators

  • Principal Investigator: Robert M Erskine, Liverpool John Moores University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2019

Primary Completion (Actual)

September 30, 2021

Study Completion (Actual)

September 30, 2023

Study Registration Dates

First Submitted

January 24, 2024

First Submitted That Met QC Criteria

January 24, 2024

First Posted (Actual)

February 1, 2024

Study Record Updates

Last Update Posted (Estimated)

February 2, 2024

Last Update Submitted That Met QC Criteria

January 31, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 19/SPS/049

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No plan to share

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe